Barclays PLC Raises Stake in Immunome, Inc. (NASDAQ:IMNM)

Barclays PLC boosted its stake in Immunome, Inc. (NASDAQ:IMNM - Free Report) by 125.9% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 105,886 shares of the company's stock after acquiring an additional 59,016 shares during the period. Barclays PLC owned 0.17% of Immunome worth $1,547,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Arizona State Retirement System boosted its stake in Immunome by 9.2% during the second quarter. Arizona State Retirement System now owns 10,862 shares of the company's stock worth $131,000 after acquiring an additional 918 shares in the last quarter. AQR Capital Management LLC raised its stake in Immunome by 34.6% during the 2nd quarter. AQR Capital Management LLC now owns 16,064 shares of the company's stock worth $194,000 after buying an additional 4,129 shares during the period. Cerity Partners LLC increased its holdings in shares of Immunome by 10.5% during the third quarter. Cerity Partners LLC now owns 53,103 shares of the company's stock valued at $776,000 after acquiring an additional 5,043 shares in the last quarter. Quest Partners LLC acquired a new position in shares of Immunome during the second quarter worth approximately $81,000. Finally, Primecap Management Co. CA lifted its holdings in shares of Immunome by 4.5% in the 3rd quarter. Primecap Management Co. CA now owns 280,800 shares of the company's stock worth $4,105,000 after purchasing an additional 12,000 shares in the last quarter. Institutional investors and hedge funds own 44.58% of the company's stock.

Insider Transactions at Immunome

In other Immunome news, insider Robert Lechleider purchased 15,805 shares of the business's stock in a transaction on Thursday, November 21st. The stock was acquired at an average price of $9.48 per share, for a total transaction of $149,831.40. Following the purchase, the insider now owns 15,805 shares of the company's stock, valued at approximately $149,831.40. This represents a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CTO Philip Tsai acquired 21,000 shares of the stock in a transaction dated Thursday, November 21st. The stock was acquired at an average price of $9.43 per share, for a total transaction of $198,030.00. Following the completion of the transaction, the chief technology officer now directly owns 21,000 shares of the company's stock, valued at approximately $198,030. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired 102,862 shares of company stock worth $978,045 over the last quarter. 8.60% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on IMNM shares. Stephens began coverage on Immunome in a report on Friday, November 8th. They set an "overweight" rating and a $30.00 price target for the company. Piper Sandler lowered their price target on shares of Immunome from $23.00 to $21.00 and set an "overweight" rating on the stock in a research report on Thursday, November 14th. Finally, Wedbush reaffirmed an "outperform" rating and issued a $33.00 price objective on shares of Immunome in a report on Monday. Seven analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $28.83.

Immunome Stock Performance

Shares of Immunome stock traded down $0.56 during trading on Monday, hitting $10.04. The company's stock had a trading volume of 1,035,892 shares, compared to its average volume of 637,222. The company has a market capitalization of $626.67 million, a PE ratio of -1.24 and a beta of 1.90. The company has a fifty day simple moving average of $11.72 and a two-hundred day simple moving average of $12.98. Immunome, Inc. has a 52 week low of $8.97 and a 52 week high of $30.96.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.